Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Sanofi, Pfizer, and others are developing therapies for the Acquired Hemophilia A treatment Acquired Hemophilia A Emerging therapies such as - BBM-H901, ISU304, TU7710, BE-101, REGV131 ...

this new agreement reaffirms Sanofi and Sobi's dedication to creating a predictable, sustainable program that addresses unmet needs and advances the standard of care for hemophilia worldwide.

Since the initial pledge, over 22,000 people with hemophilia have been treated with factor donated by Sobi and Sanofi. We are thrilled to continue our partnership with the WFH and look forward to ...

MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announce the signing ...

Sanofi's Qfitlia, approved a few days ago by the FDA, offers a competitive edge in the hemophilia market with fewer injections and broader applicability than rivals. Despite Qfitlia's promising ...

Also Read: Sanofi Strengthens Its Immune System-Focused ... Qfitlia helps increase thrombin generation to restore hemostasis in hemophilia patients. In the ATLAS clinical development program ...